Manufacturing & Production

Eli Lilly plans to invest $450m at production site in Research Triangle Park

US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US.
Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel.
Since 2020, Lilly has invested almost $4bn, $1.7bn of which has gone towards the development and expansion of its campus at the Research Triangle Park. The preliminary manufacturing is expected to begin this year at the newly expanded site, with preparations for FDA inspections under way.
The expansion is expected to allow the company to continue to supply patients with new medications and aims to set up the global distribution of its products.
Edgardo Hernandez, Lilly’s Manufacturing Operations executive vice president and president, commented: “As we move into 2023, Lilly is focused on finding innovative solutions to meet the growing demand for our medicines. […] Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients can rely on to address serious health challenges like diabetes. […] We’re on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future.”